News

For East Asian adults with transthyretin amyloid cardiomyopathy (ATTR-CM), the approved therapy Amvuttra (vutrisiran) is a safe and effective treatment, with…

The plasma protein transthyretin (TTR) transports retinol-binding protein and thyroxine1.Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cause of…

Tafamidis (Vyndaqel/Vyndamax) stabilizes transthyretin (TTR) tetramer, preventing amyloidogenesis. It is the only approved disease-modifying therapy in ATTR…

Patisiran (Onpattro) and inotersen (Tegsedi) are TTR mRNA silencing therapies in hereditary ATTR amyloidosis (hATTR). Patisiran is lipid nanoparticle RNAi (siRNA),…

Acoramidis provides consistent clinical benefit in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) irrespective of baseline atrial…

AbstractIntroduction and objectives: To describe the clinical characteristics of patients with cardiac amyloidosis who have undergone heart transplantation (HT).…

Background: Transthyretin amyloidosis (ATTR) is an underdiagnosed cause of cardiomyopathy that is gaining recognition as new treatments become available. The…

The incidence and prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) increased markedly in the US between 2010 and 2023, according to a study published in…

A computerized test that measures how quickly and accurately people perform finger tapping and hand movement tasks was able to detect subtle motor problems in…

AbstractPurposeTo provide an overview of the manifestation and diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and the treatment option acoramidis,…